|
|
Article: Research from L. Lazo and colleagues has provided new data on dengue fever.
- Article from:
- Vaccine Weekly
- Article date:
- May 13, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
"A vaccine against dengue virus must be able to induce an effective and equivalent immune response to the four viral serotypes; however, some studies have revealed that DEN4 (dengue-virus serotype 4) induces a weaker immune response than the others in quadrivalent (tetravalent') formulations. We have previously reported the protective capacity, in a viral encephalitis murine model, of fusion protein P64k-envelope domain III of DEN1, DEN2 and DEN3," scientists writing in the journal Biotechnology and Applied Biochemistry report (see also Dengue Fever).
"We also reported that the P64k protein can be used as a carrier in two different positions: the insertion ...